These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15243154)

  • 1. Immunotherapy for Alzheimer's disease.
    McGeer PL; McGeer E
    Sci Aging Knowledge Environ; 2004 Jul; 2004(27):pe29. PubMed ID: 15243154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide.
    Lue LF; Walker DG
    J Neurosci Res; 2002 Nov; 70(4):599-610. PubMed ID: 12404514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response.
    Zou J; Yao Z; Zhang G; Wang H; Xu J; Yew DT; Forster EL
    J Neurol Sci; 2008 Sep; 272(1-2):87-98. PubMed ID: 18571202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain.
    Kim HD; Kong FK; Cao Y; Lewis TL; Kim H; Tang DC; Fukuchi K
    Neurosci Lett; 2004 Nov; 370(2-3):218-23. PubMed ID: 15488326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-beta immunotherapies in mice and men.
    Brendza RP; Holtzman DM
    Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model.
    Matsuda J; Kaminaka K; Nozaki C
    Biochem Biophys Res Commun; 2009 Apr; 382(1):149-52. PubMed ID: 19265678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
    Boche D; Denham N; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.
    Wang CY; Finstad CL; Walfield AM; Sia C; Sokoll KK; Chang TY; Fang XD; Hung CH; Hutter-Paier B; Windisch M
    Vaccine; 2007 Apr; 25(16):3041-52. PubMed ID: 17287052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonviral DNA vaccination augments microglial phagocytosis of beta-amyloid deposits as a major clearance pathway in an Alzheimer disease mouse model.
    Okura Y; Kohyama K; Park IK; Matsumoto Y
    J Neuropathol Exp Neurol; 2008 Nov; 67(11):1063-71. PubMed ID: 18957895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
    Vasilevko V; Cribbs DH
    Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele.
    Zota V; Nemirovsky A; Baron R; Fisher Y; Selkoe DJ; Altmann DM; Weiner HL; Monsonego A
    J Immunol; 2009 Sep; 183(5):3522-30. PubMed ID: 19675171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.
    Nicoll JA; Wilkinson D; Holmes C; Steart P; Markham H; Weller RO
    Nat Med; 2003 Apr; 9(4):448-52. PubMed ID: 12640446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
    Schenk D
    Nat Rev Neurosci; 2002 Oct; 3(10):824-8. PubMed ID: 12360327
    [No Abstract]   [Full Text] [Related]  

  • 16. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide.
    Townsend KP; Town T; Mori T; Lue LF; Shytle D; Sanberg PR; Morgan D; Fernandez F; Flavell RA; Tan J
    Eur J Immunol; 2005 Mar; 35(3):901-10. PubMed ID: 15688347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune system, amyloid-beta peptide, and Alzheimer's disease.
    Weksler ME; Gouras G; Relkin NR; Szabo P
    Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
    Solomon B
    Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active Aβ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Aβ42-driven pathology.
    Nemirovsky A; Shapiro J; Baron R; Kompaniets A; Monsonego A
    J Neuroimmunol; 2012 Jun; 247(1-2):95-9. PubMed ID: 22498096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy as treatment for Alzheimer's disease.
    Hawkes CA; McLaurin J
    Expert Rev Neurother; 2007 Nov; 7(11):1535-48. PubMed ID: 17997702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.